{"title_page": "Becampanel", "text_new": "{{Drugbox\n| IUPAC_name        = ({[(2,3-Dihydroxy-7-nitro-5-quinoxalinyl)methyl]amino}methyl)phosphonic acid\n| image             = Becampanel.svg\n| CAS_number        = 188696-80-2\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = X3D0O800AJ\n| ATC_prefix        = None\n| ATC_suffix        = \n| PubChem           = 5491960\n| DrugBank          = \n| ChemSpiderID      = 4590791\n| chemical_formula =\n| C=10 | H=11 | N=4 | O=7 | P=1\n| molecular_weight  = 330.191 g/mol\n| smiles            = c1c(cc2c(c1CNCP(=O)(O)O)[nH]c(=O)c(=O)[nH]2)[N+](=O)[O-]\n| StdInChI          = 1S/C10H11N4O7P/c15-9-10(16)13-8-5(3-11-4-22(19,20)21)1-6(14(17)18)2-7(8)12-9/h1-2,11H,3-4H2,(H,12,15)(H,13,16)(H2,19,20,21)\n| StdInChIKey       = ABFMMCZFKUIJGQ-UHFFFAOYSA-N\n| bioavailability   = \n| protein_bound     = \n| metabolism        = \n| elimination_half-life = \n| excretion         = \n| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->\n| pregnancy_US      =  <!-- A / B            / C / D / X -->\n| pregnancy_category=  \n| legal_AU =  <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->\n| legal_CA =  <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->\n| legal_UK =  <!-- GSL, P, POM, CD, or Class A, B, C -->\n| legal_US =  <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->\n| legal_status      = \n| routes_of_administration = \n}}\n\n'''Becampanel''' ([[International Nonproprietary Name|INN]]) (code name '''AMP397''') is a [[quinoxalinedione]] [[chemical derivative|derivative]] [[drug]] which acts as a [[competitive antagonist]] of the [[AMPA receptor]] ([[IC50|IC<sub>50</sub>]] = 11 nM).<ref name=\"TaylorTriggle2007\">{{cite book|author1=John B. Taylor|author2=D. J. Triggle|title=Comprehensive medicinal chemistry II|url=https://books.google.com/books?id=fIMvAQAAIAAJ|year=2007|publisher=Elsevier|isbn=978-0-08-044513-7|page=290}}</ref><ref name=\"pmid17874969\">{{cite journal |vauthors=Kwan P, Brodie MJ | title = Emerging drugs for epilepsy | journal = Expert Opin Emerg Drugs | volume = 12 | issue = 3 | pages = 407\u201322 |date=September 2007  | pmid = 17874969 | doi = 10.1517/14728214.12.3.407 }}</ref><ref name=\"pmid24387310\">{{cite journal |vauthors=Citraro R, Aiello R, Franco V, De Sarro G, Russo E | title = Targeting \u03b1-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy | journal = Expert Opin. Ther. Targets | volume = 18 | issue = 3 | pages = 319\u201334 |date=March 2014  | pmid = 24387310 | doi = 10.1517/14728222.2014.874416 }}</ref><ref name=\"Organization1988\">{{cite book|author=World Health Organization|title=International Nonproprietary Names (INN) for Pharmaceutical Substances|url=https://books.google.com/books?id=dcF1nQEACAAJ|year=1988|publisher=W.H.O.|isbn=9789240560369}}</ref> It was investigated as an [[anticonvulsant]] for the treatment of [[epilepsy]] by [[Novartis]], and was also looked at as a potential treatment for [[neuropathic pain]] and [[cerebral ischemia]], but never completed [[clinical trial]]s.<ref name=\"TaylorTriggle2007\" /><ref name=\"pmid17874969\" /><ref name=\"pmid24387310\" /><ref name=\"pmid20603226\">{{cite journal |vauthors=Pathan SA, Jain GK, Akhter S, Vohora D, Ahmad FJ, Khar RK | title = Insights into the novel three 'D's of epilepsy treatment: drugs, delivery systems and devices | journal = Drug Discov. Today | volume = 15 | issue = 17\u201318 | pages = 717\u201332 |date=September 2010  | pmid = 20603226 | doi = 10.1016/j.drudis.2010.06.014 }}</ref>\n\n==References==\n{{Reflist|2}}\n\n{{Anticonvulsants}}\n{{Ionotropic glutamate receptor modulators}}\n\n[[Category:AMPA receptor antagonists]]\n[[Category:Amines]]\n[[Category:Anticonvulsants]]\n[[Category:Nitro compounds]]\n[[Category:Quinoxalines]]\n[[Category:Abandoned drugs]]\n\n\n\n{{anticonvulsant-stub}}\n", "text_old": "{{Drugbox\n| IUPAC_name        = ({[(2,3-Dihydroxy-7-nitro-5-quinoxalinyl)methyl]amino}methyl)phosphonic acid\n| image             = Becampanel.svg\n| CAS_number        = 188696-80-2\n| ATC_prefix        = None\n| ATC_suffix        = \n| PubChem           = 5491960\n| DrugBank          = \n| ChemSpiderID      = 4590791\n| chemical_formula =\n| C=10 | H=11 | N=4 | O=7 | P=1\n| molecular_weight  = 330.191 g/mol\n| smiles            = c1c(cc2c(c1CNCP(=O)(O)O)[nH]c(=O)c(=O)[nH]2)[N+](=O)[O-]\n| StdInChI          = 1S/C10H11N4O7P/c15-9-10(16)13-8-5(3-11-4-22(19,20)21)1-6(14(17)18)2-7(8)12-9/h1-2,11H,3-4H2,(H,12,15)(H,13,16)(H2,19,20,21)\n| StdInChIKey       = ABFMMCZFKUIJGQ-UHFFFAOYSA-N\n| bioavailability   = \n| protein_bound     = \n| metabolism        = \n| elimination_half-life = \n| excretion         = \n| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->\n| pregnancy_US      =  <!-- A / B            / C / D / X -->\n| pregnancy_category=  \n| legal_AU =  <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->\n| legal_CA =  <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->\n| legal_UK =  <!-- GSL, P, POM, CD, or Class A, B, C -->\n| legal_US =  <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->\n| legal_status      = \n| routes_of_administration = \n}}\n\n'''Becampanel''' ([[International Nonproprietary Name|INN]]) (code name '''AMP397''') is a [[quinoxalinedione]] [[chemical derivative|derivative]] [[drug]] which acts as a [[competitive antagonist]] of the [[AMPA receptor]] ([[IC50|IC<sub>50</sub>]] = 11 nM).<ref name=\"TaylorTriggle2007\">{{cite book|author1=John B. Taylor|author2=D. J. Triggle|title=Comprehensive medicinal chemistry II|url=https://books.google.com/books?id=fIMvAQAAIAAJ|year=2007|publisher=Elsevier|isbn=978-0-08-044513-7|page=290}}</ref><ref name=\"pmid17874969\">{{cite journal |vauthors=Kwan P, Brodie MJ | title = Emerging drugs for epilepsy | journal = Expert Opin Emerg Drugs | volume = 12 | issue = 3 | pages = 407\u201322 |date=September 2007  | pmid = 17874969 | doi = 10.1517/14728214.12.3.407 }}</ref><ref name=\"pmid24387310\">{{cite journal |vauthors=Citraro R, Aiello R, Franco V, De Sarro G, Russo E | title = Targeting \u03b1-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy | journal = Expert Opin. Ther. Targets | volume = 18 | issue = 3 | pages = 319\u201334 |date=March 2014  | pmid = 24387310 | doi = 10.1517/14728222.2014.874416 }}</ref><ref name=\"Organization1988\">{{cite book|author=World Health Organization|title=International Nonproprietary Names (INN) for Pharmaceutical Substances|url=https://books.google.com/books?id=dcF1nQEACAAJ|year=1988|publisher=W.H.O.|isbn=9789240560369}}</ref> It was investigated as an [[anticonvulsant]] for the treatment of [[epilepsy]] by [[Novartis]], and was also looked at as a potential treatment for [[neuropathic pain]] and [[cerebral ischemia]], but never completed [[clinical trial]]s.<ref name=\"TaylorTriggle2007\" /><ref name=\"pmid17874969\" /><ref name=\"pmid24387310\" /><ref name=\"pmid20603226\">{{cite journal |vauthors=Pathan SA, Jain GK, Akhter S, Vohora D, Ahmad FJ, Khar RK | title = Insights into the novel three 'D's of epilepsy treatment: drugs, delivery systems and devices | journal = Drug Discov. Today | volume = 15 | issue = 17\u201318 | pages = 717\u201332 |date=September 2010  | pmid = 20603226 | doi = 10.1016/j.drudis.2010.06.014 }}</ref>\n\n==References==\n{{Reflist|2}}\n\n{{Anticonvulsants}}\n{{Ionotropic glutamate receptor modulators}}\n\n[[Category:AMPA receptor antagonists]]\n[[Category:Amines]]\n[[Category:Anticonvulsants]]\n[[Category:Nitro compounds]]\n[[Category:Quinoxalines]]\n[[Category:Abandoned drugs]]\n\n\n\n{{anticonvulsant-stub}}\n", "name_user": "Fswitzer4", "label": "safe", "comment": "added FDA UNII to drug box", "url_page": "//en.wikipedia.org/wiki/Becampanel"}
